Venmax Drugs & Pharmaceuticals Intrinsic Value
Venmax Drugs & Pharmaceuticals (VENMAX) median intrinsic value is ₹7.42 from 6 valuation models (range ₹5–₹23), vs current price ₹18.00 — -58.8% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit VENMAX screener.
VENMAX Valuation Methods Summary — DCF, Graham Number & P/E
Venmax Drugs & Pharmaceuticals intrinsic value across 6 models vs current price ₹18.00 — upside/downside and value range per method. Analyse Venmax Drugs & Pharmaceuticals shareholding analysis to track promoter, FII and institutional holdings.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹5.40 | ₹4.32 - ₹6.48 | -70.0% | EPS: ₹0.21, Sector P/E: 22x |
| Book Value Method | asset | ₹23.33 | ₹21.00 - ₹25.66 | +29.6% | Book Value/Share: ₹11.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹13.33 | ₹12.00 - ₹14.66 | -25.9% | Revenue/Share: ₹6.67, P/S: 2.0x |
| PEG Ratio Method | growth | ₹5.40 | ₹4.86 - ₹5.94 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹5.40 | ₹4.86 - ₹5.94 | -70.0% | Revenue Growth: 15.0%, Adj P/E: 16.1x |
| Graham Defensive Method | conservative | ₹7.42 | ₹6.68 - ₹8.16 | -58.8% | EPS: ₹0.21, BVPS: ₹11.67 |
VENMAX Intrinsic Value vs Market Price — All Valuation Models
Venmax Drugs & Pharmaceuticals fair value range ₹5–₹23 vs current market price ₹18.00 across 6 valuation models. Read VENMAX dividend payout details for the complete payout history and dividend yield track record.
VENMAX Intrinsic Value Analysis — Undervalued or Overvalued?
Venmax Drugs & Pharmaceuticals median intrinsic value ₹7.42, current price ₹18.00 — Trading Above Calculated Value by 58.8%, margin of safety -100.0%.
What is the intrinsic value of VENMAX?
Based on our comprehensive analysis using 6 different valuation methods, the estimated intrinsic value of Venmax Drugs & Pharmaceuticals (VENMAX) is ₹7.42 (median value). With the current market price of ₹18.00, this represents a -58.8% variance from our estimated fair value.
The valuation range spans from ₹5.40 to ₹23.33, indicating ₹5.40 - ₹23.33.
Is VENMAX undervalued or overvalued?
Based on our multi-method analysis, Venmax Drugs & Pharmaceuticals (VENMAX) appears to be trading above calculated value by approximately 58.8%.
VENMAX Financial Health — Key Ratios vs Industry Benchmarks
Venmax Drugs & Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Operating Margin | 2.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.50x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
VENMAX Cash Flow Quality — Operating & Free Cash Flow
Venmax Drugs & Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-2 Cr | ₹-2 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |